TABLE 3.

Summary of IgM and IgG data against specific antigens among patients with systemic candidiasis versus controls

Predictor variableMean log2 titer ± SE of sera from:P valuea% of patients with systemic candidiasis with detectable titers (no. with detectable titers/total no. of patients)
Patients with systemic candidiasisControls
IgM titers
    MET6-14.57 ± 0.284.93 ± 0.48NS25 (15/60)
    MET6-24.16 ± 0.234.80 ± 0.44NS18.3 (11/60)
    NOT56.52 ± 0.334.35 ± 0.420.000363.3 (38/60)
    SET16.71 ± 0.344.65 ± 0.490.00165 (39/60)
    RBT45.37 ± 0.324.12 ± 0.380.0341.7 (25/60)
    IPF91626.96 ± 0.344.30 ± 0.26<0.000168.3 (41/60)
    CAR15.41 ± 0.314.22 ± 0.370.0343.3 (26/60)
    GAP13.75 ± 0.174.22 ± 0.37NS10 (6/60)
    ENO15.62 ± 0.334.30 ± 0.410.0246.7 (28/60)
    BGL24.40 ± 0.264.62 ± 0.43NS23.3 (14/60)
    FBA15.16 ± 0.324.26 ± 0.38NS36.7 (22/60)
    MUC1-13.90 ± 0.194.48 ± 0.42NS13.3 (8/60)
    MUC1-24.29 ± 0.254.13 ± 0.38NS20 (12/60)
    PGK1-15.57 ± 0.343.56 ± 0.230.000544.1 (26/59)*
    PGK1-24.12 ± 0.233.97 ± 0.36NS20.3 (12/59)*
IgG titers
    MET6-18.67 ± 0.286.28 ± 0.500.000293.3 (56/60)
    MET6-29.60 ± 0.218.57 ± 0.480.0298.3 (59/60)
    NOT58.18 ± 0.373.74 ± 0.23<0.000185 (51/60)
    SET19.16 ± 0.224.51 ± 0.36<0.000198.3 (59/60)
    RBT49.42 ± 0.274.78 ± 0.40<0.000198.3 (59/60)
    IPF91628.92 ± 0.225.14 ± 0.39<0.000196.7 (58/60)
    CAR18.40 ± 0.284.28 ± 0.35<0.000190 (54/60)
    GAP18.38 ± 0.293.74 ± 0.23<0.000191.7 (55/60)
    ENO19.07 ± 0.264.46 ± 0.38<0.000198.3 (59/60)
    BGL28.69 ± 0.274.32 ± 0.36<0.000195 (57/60)
    FBA18.49 ± 0.293.60 ± 0.19<0.000193.3 (56/60)
    MUC1-18.72 ± 0.235.86 ± 0.56<0.000196.7 (58/60)
    MUC1-28.69 ± 0.247.02 ± 0.520.00195 (57/60)
    PGK1-17.93 ± 0.272.20 ± 0.460.0191.5 (54/59)b
    PGK1-27.49 ± 0.266.52 ± 0.430.0589.8 (53/59)b
  • a NS, not significant.

  • b One patient with systemic candidiasis and one control did not have sufficient sera to test against PGK1-1 and PGK1-2.